Annexon Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the Annexon investor event. At this time, all attendees are in a listen-only mode. A live question-and-answer session will follow the formal presentations. To our covering analysts, please use the raise hand feature to be added to the queue. As a reminder, this call is being recorded, and a replay will be available on the Annexon website following the conclusion of the event. I will now turn the call over to Douglas Love, Chief Executive Officer of Annexon. Please go ahead, Doug. Thank you, Wilson.
Welcome, everyone, and thank you for joining us this morning. We are pleased to be advancing towards the readout this quarter of the month 15 primary endpoint for our ARCHER II phase III trial in geographic atrophy, and we appreciate you listening in as we provide an overview of this promising program and what to expect with the readout ahead. We will be making forward-looking statements this morning, and you can refer to our SEC filings for more information. Next slide. Joining me on the call this morning is retina specialist Dr. Roger Goldberg of Bay Area Retina Associates, who will share clinical perspectives on the GA marketplace. We are also joined by Dr. Lloyd Clark, himself a retina specialist and our SVP of Ophthalmology Strategy and Innovation, who will walk through the ARCHER phase II data and ARCHER II phase III trial design and execution.
Lastly, joining us for Q&A is Dr. Ted Yednock, our Chief Innovation Officer and one of our retina biology experts. Next slide. Regarding this morning's agenda, we will spend approximately 45 minutes in prepared remarks on the GA market and our vision-sparing pivotal program, and we will then invite you to join us for a Q&A session. All righty, next slide. Before diving into the meat of the program, I would like to quickly provide a little background on Annexon for those who are less familiar. Annexon was spun out of Stanford University based on discoveries there on the role of C1q as the initiator of harmful classical complement inflammation in a host of neuroinflammatory diseases. Built on more than two decades of research on C1q and classical complement biology, Annexon's novel platform is designed to stop neuroinflammation at its source in the body, brain, and eye before tissue damage becomes irreversible.
By providing comprehensive protection against harmful complement inflammation, and consistent with our mission to help millions live their best lives, we have intentionally focused on preserving function or independence for those living with devastating neuroinflammatory diseases. We are encouraged by what our platform has demonstrated thus far and even more encouraged by what is ahead. Next slide. Today, our complement platform is translated into two late-stage programs with blockbuster potential in large underserved markets. GBS is our most advanced program, having demonstrated the first winning placebo-controlled dataset in this devastating disease in nearly half a century. Thereby blocking C1q inflammation in the body and brain, tanruprubart has protected peripheral nerves and function, and approximately 90% of treated patients in our pivotal phase III trial improved by week one, which gave them a 2.5 times greater likelihood to being fully recovered from acute paralysis by week 26.
Tanruprubart treatment has also shown unprecedented outcomes in the ongoing U.S. European FORWARD study, where 100% of patients have responded to treatment thus far. The net-net is that by stopping C1q inflammation where it starts on diseased tissue, that can result in profound functional outcomes. We have filed for approval for the treatment of GBS in the EU, and we anticipate filing the U.S. BLA this quarter. Today's event, however, is focused on the program on the right, our GA program, where we're targeting C1q in the retina with vonaprument to preserve synapses and neurons necessary to protect against vision loss. Our phase II GA trial is the first and only to show significant vision preservation in a randomized sham-controlled study, where we protected vision on several measures, as well as photoreceptor neurons responsible for visual acuity.
ARCHER II is a highly differentiated phase III study with vision as the primary endpoint and why we're here today. We want to ensure that you understand this first-in-kind vision-sparing pivotal program that is unlike any prior approaches. Next slide. One other thing. It's important to note that we didn't simply advance from phase II to phase III. We made the ARCHER II phase III trial better by incorporating key learnings from the phase II and other programs to conduct what may be the most comprehensive and informed vision-sparing pivotal GA study to date.
ARCHER II has been intentionally designed to maximize the probability of success by replicating the vision protection demonstrated in the phase II study, and as Lloyd will describe, the phase III trial is deliberately studying patient populations likely to lose vision over the course of the trial, coupled with patient populations where vonaprument has shown a dose-dependent treatment effect. We're particularly encouraged by the breadth and depth of patient populations where vonaprument has shown robust activity, which is exceedingly important in a disease such as geographic atrophy. It's also noteworthy that the phase III trial is larger, longer, and better powered than the phase II, all of which we believe enhances the likelihood of success when we report out on the 15-month primary analysis later this quarter.
With that backdrop, I'll now pass the mic over to Dr. Roger Goldberg to provide an overview of what vision protection means to GA patients and physicians.
Dr. Goldberg? Great. Thank you so much, Doug, and great to be here, really to discuss where we are right now with geographic atrophy from a clinical perspective, what I hear from my patients, and what it would mean if we had a drug available that could actually slow down or reduce the risk of significant vision loss in geographic atrophy.
If we could go to the next slide, please. We have two FDA-approved medicines, SYFOVRE and IZERVAY, and they have been available since a couple years now on the market, a couple years now, I think 2023, 2024. There is still a huge unmet need, however, because although these two agents demonstrated the ability to slow down the growth of geographic atrophy, they have not been able to show down any protection of vision, of actually preserving the vision.
GA, despite these therapies, is still a leading cause of blindness in the elderly. I hear literally every single day about the impact that geographic atrophy has on my patients' lives, their ability to function independently. Although here it says on the top right of the slide that the average age is 79 for a patient with geographic atrophy, I will tell you clinically, there is a huge range. It is not uncommon to see patients with GA in their 60s, still highly functional, but seeing that progression from intermediate AMD into the advanced dry form of AMD, which we call geographic atrophy, and seeing patients on the other end, 90-year-olds also with geographic atrophy. So a huge range. With that huge range, I would also comment, is a huge range in the functional capabilities of people when they walk in our clinic with geographic atrophy.
I have 90-year-old patients who still drive and kind of live a really robust and full life and are frankly quite worried about their vision because the rest of their body and brains are still functioning quite well. So, there is a huge variability in terms of the severity of the disease, the age of the patients, and we know with this rising baby boomer population that the incidence of GA is only going to increase here in this country and frankly throughout the rest of the world as well. If you go to the next slide, please. This is some survey work done actually for an FDA panel to try to incorporate the patient voice as we think about designing clinical trials for geographic atrophy. One of the things you will notice that patients do not care about is lesion growth.
That is never something that comes out of a patient's mouth is, "Well, how is my GA lesion growing?" What they care about is their vision and the way that they use their vision. We hear things all the time about difficulty recognizing faces, of course, driving in this country. I am in the San Francisco Bay Area. Although we have public transportation, I would say this is, other than frankly probably New York City, we do not have a really robust public transportation system in this country. Patients really rely on driving. You see here reading or watching TV. I hear a lot about this. Patients kind of sit there and scratch their head and say, "Geez, I even upgraded to a larger TV, and I am still having trouble.
I cannot read the news ticker that comes across the bottom of the television." On the right, I would say, is more of the emotional component, and this survey, I think, replicates many other peer-reviewed publications that show this high concordance with geographic atrophy, vision loss, and depression. They basically, it is this feeling and concern about losing their independence, the stress of the unknown. How quickly am I going to lose my vision? Is there anything I can do about it to slow that down? Caring for their family, obviously losing the ability to drive, all these things that I think couple into a concurrent epidemic in this country in older people is this epidemic of loneliness.
When they have vision loss associated with their geographic atrophy, they actually tend to withdraw a little bit, and it exacerbates their ability to socially interact with others, and I think exacerbates the loneliness that is also going on here. A lot of these things, of course, as you can imagine, are multifactorial, but point being, huge and profound impact on the patient's quality of life. If you could go to the next slide, please. This is not only a significant but a rapidly growing unmet need. In the U.S., there are about 1.5 million people affected by geographic atrophy. Actually, slightly more than that in the EU, 2.5 million people, over 8 million people worldwide with geographic atrophy. Of course, here in the U.S., we do have two FDA-approved medicines.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
